149 related articles for article (PubMed ID: 25765906)
1. Indirubin 3'-(O-oxiran-2-ylmethyl)oxime: a novel anticancer agent.
Ichimaru Y; Saito H; Uchiyama T; Metori K; Tabata K; Suzuki T; Miyairi S
Bioorg Med Chem Lett; 2015 Apr; 25(7):1403-6. PubMed ID: 25765906
[TBL] [Abstract][Full Text] [Related]
2. 5-Bromoindirubin 3'-(O-oxiran-2-ylmethyl)oxime: A long-acting anticancer agent and a suicide inhibitor for epoxide hydrolase.
Ichimaru Y; Fujii T; Saito H; Sano M; Uchiyama T; Miyairi S
Bioorg Med Chem; 2017 Sep; 25(17):4665-4676. PubMed ID: 28743492
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and antitumor activity evaluation of steroidal oximes.
Gomes AR; Pires AS; Abrantes AM; Gonçalves AC; Costa SC; Varela CL; Silva ET; Botelho MF; Roleira FMF
Bioorg Med Chem; 2021 Sep; 46():116360. PubMed ID: 34425478
[TBL] [Abstract][Full Text] [Related]
4. Indirubin-3-monooxime induced cell cycle arrest and apoptosis in Hep-2 human laryngeal carcinoma cells.
Kameswaran TR; Ramanibai R
Biomed Pharmacother; 2009 Feb; 63(2):146-54. PubMed ID: 18450412
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine.
White AW; Carpenter N; Lottin JR; McClelland RA; Nicholson RI
Eur J Med Chem; 2012 Oct; 56():246-53. PubMed ID: 22995819
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents.
Wang R; Zhang X; Song H; Zhou S; Li S
Bioorg Med Chem Lett; 2014 Sep; 24(17):4304-7. PubMed ID: 25127868
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of Synthesized 1,4-Naphthoquinone Oxime Derivatives on Selected Human Cancer Cell Lines.
Zhang Q; Dong J; Cui J; Huang G; Meng Q; Li S
Chem Pharm Bull (Tokyo); 2018; 66(6):612-619. PubMed ID: 29863062
[TBL] [Abstract][Full Text] [Related]
8. Indirubin 3'-oxime inhibits anticancer agent-induced YB-1 nuclear translocation in HepG2 human hepatocellular carcinoma cells.
Tanaka T; Ohashi S; Saito H; Wada T; Aoyama T; Ichimaru Y; Miyairi S; Kobayashi S
Biochem Biophys Res Commun; 2018 Jan; 496(1):7-11. PubMed ID: 29274785
[TBL] [Abstract][Full Text] [Related]
9. Mechanism responsible for inhibitory effect of indirubin 3'-oxime on anticancer agent-induced YB-1 nuclear translocation in HepG2 human hepatocellular carcinoma cells.
Tanaka T; Kasai M; Kobayashi S
Exp Cell Res; 2018 Sep; 370(2):454-460. PubMed ID: 29981748
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of 3-ylideneoxindole acetamides as potent anticancer agents.
Chiou CT; Lee WC; Liao JH; Cheng JJ; Lin LC; Chen CY; Song JS; Wu MH; Shia KS; Li WT
Eur J Med Chem; 2015 Jun; 98():1-12. PubMed ID: 25988923
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of sulfur-containing shikonin oxime derivatives as potential antineoplastic agents.
Huang G; Zhao HR; Meng QQ; Zhang QJ; Dong JY; Zhu BQ; Li SS
Eur J Med Chem; 2018 Jan; 143():166-181. PubMed ID: 29174813
[TBL] [Abstract][Full Text] [Related]
12. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death.
Ribas J; Bettayeb K; Ferandin Y; Knockaert M; Garrofé-Ochoa X; Totzke F; Schächtele C; Mester J; Polychronopoulos P; Magiatis P; Skaltsounis AL; Boix J; Meijer L
Oncogene; 2006 Oct; 25(47):6304-18. PubMed ID: 16702956
[TBL] [Abstract][Full Text] [Related]
13. 5-diphenylacetamido-indirubin-3'-oxime as a novel mitochondria-targeting agent with anti-leukemic activities.
Song JH; Lee JE; Cho KM; Park SH; Kim HJ; Kim YC; Kim TS
Mol Carcinog; 2016 May; 55(5):611-21. PubMed ID: 25788004
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel steroidal 5α,8α-epidioxyandrost-6-ene-3β-ol-17-(O-phenylacetamide)oxime derivatives as potential anticancer agents.
Bu M; Cao T; Li H; Guo M; Yang BB; Zeng C; Zhou Y; Zhang N; Hu L
Bioorg Med Chem Lett; 2017 Aug; 27(16):3856-3861. PubMed ID: 28666736
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9.
Yan L; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2015 Jun; 25(11):2447-51. PubMed ID: 25908517
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacological evaluation of novel bisindolylalkanes analogues.
Song YL; Dong YF; Yang T; Zhang CC; Su LM; Huang X; Zhang DN; Yang GL; Liu YX
Bioorg Med Chem; 2013 Dec; 21(24):7624-7. PubMed ID: 24262885
[TBL] [Abstract][Full Text] [Related]
17. Modulation of glioma-inflammation crosstalk profiles in human glioblastoma cells by indirubin-3'-(2,3 dihydroxypropyl)-oximether (E804) and 7-bromoindirubin-3'-oxime (7BIO).
Scobie MR; Houke HR; Rice CD
Chem Biol Interact; 2019 Oct; 312():108816. PubMed ID: 31505164
[TBL] [Abstract][Full Text] [Related]
18. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel indolin-2-ones as potent anticancer compounds.
Zhou A; Yan L; Lai F; Chen X; Goto M; Lee KH; Xiao Z
Bioorg Med Chem Lett; 2017 Aug; 27(15):3326-3331. PubMed ID: 28625363
[TBL] [Abstract][Full Text] [Related]
20. 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.
Choi SJ; Lee JE; Jeong SY; Im I; Lee SD; Lee EJ; Lee SK; Kwon SM; Ahn SG; Yoon JH; Han SY; Kim JI; Kim YC
J Med Chem; 2010 May; 53(9):3696-706. PubMed ID: 20361800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
